AI listens to your voice to spot diabetes stress
NCT ID NCT06985862
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study explores whether artificial intelligence can detect stress in people with type 1 diabetes by analyzing their voice recordings. Participants record their voice four times a day for a period. The goal is to develop a tool that helps patients and doctors better understand and manage stress, which can affect blood sugar levels. The study is currently suspended and involves 35 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Voice recording and AI analysis
What this could lead to
If successful, this could lead to a tool that helps people with type 1 diabetes better manage stress and improve blood sugar control.
What could go wrong
This is a small, early-stage study that is currently suspended. The AI tool may not accurately detect stress or lead to practical benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Angers University Hospital
Angers, Site Principal Investigator, 49100, France
-
CERITD (Centre d'Etudes et de Recherches pour l'Intensification du Traitement du Diabète)
Évry, 91058, France
-
Grenoble University Hospital
Grenoble, 38043, France
-
Rennes University Hospital
Rennes, France, 35200, France
-
Strasbourg University Hospital
Strasbourg, France, 67091, France